Cardiogram
AI-powered heart health monitoring platform using wearable device data
Platform · Cloud SaaSCompany source
Company profile
About Cardiogram
Cardiogram is a health technology company that leverages artificial intelligence and wearable device data to detect and predict cardiovascular conditions and other health issues. The company develops deep learning algorithms that analyze heart rate data from consumer wearables like smartwatches and fitness trackers to identify patterns associated with conditions such as atrial fibrillation, sleep apnea, hypertension, and diabetes. Cardiogram's technology transforms passive health monitoring into actionable clinical insights, enabling early detection and intervention for cardiovascular disease. The company's AI models have been validated through clinical research and partnerships with academic institutions. Cardiogram serves both consumers through direct-to-consumer applications and healthcare organizations through enterprise partnerships, making cardiovascular screening more accessible and continuous. By combining the ubiquity of wearable devices with advanced machine learning, Cardiogram aims to democratize heart health monitoring and enable proactive, preventive care at scale.
Company description Cardiogram official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Cardiogram?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- atrial fibrillation
- cardiovascular disease
- diabetes
- hypertension
- sleep apnea
Who it serves
- consumers
- healthcare organizations
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Device closure via minimally invasive left intercostal incision in children with perimembranous ventricular septal defect.Scientific reports · Nov 2, 2024
[Pachymic acid protects against Crohn's disease-like intestinal barrier injury and colitis in miceby suppressingintestinal epithelial cell apoptosis via inhibiting PI3K/AKT signaling].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · Jun 20, 2023
LncRNA SNHG7 promotes glioma cells viability, migration and invasion by regulating miR-342-3p/AKT2 axis.The International journal of neuroscience · Dec 1, 2021
Characteristics of olfactory ensheathing cells and microarray analysis in Tupaia belangeri (Wagner, 1841).Molecular medicine reports · Aug 1, 2019
Associations between endothelial nitric oxide synthase gene polymorphisms and the risk of coronary artery disease: A systematic review and meta-analysis of 132 case-control studies.European journal of preventive cardiology · Jan 1, 2019
Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.Annals of translational medicine · Dec 1, 2018
Clinical validation
Clinical-trial records
Phase 1 Study on the Safety, Tolerability, and Pharmacokinetics of JST-018 in Healthy AdultsNCT07595458 · Mentioned · RECRUITING
Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy AdultsNCT06943378 · Mentioned · ACTIVE NOT RECRUITING
Post-concussion Syndrome and ChiropracticNCT06151184 · Mentioned · TERMINATED
Study of the Effect of Hydrocortisone Administered for the Prevention of Pulmonary Bronchodysplasia (PREMILOC Trial) on the Determinants of Systemic Blood Pressure in Children (PREMILOCAP)NCT05451264 · Mentioned · COMPLETED
Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol SepsisNCT07286643 · Mentioned · RECRUITING
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)NCT02316314 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Cardiogram
Recent articles published on Cardiogram's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.